News

Public · Published

Eli Lilly defeats Novo Nordisk attempt to halt weight-loss drug ads

A US judge denied Novo Nordisk's bid to stop Eli Lilly's weight-loss drug advertisements. Novo Nordisk claimed the ads for Zepbound and Mounjaro were false and misleading. The judge said Novo Nordisk did not show the ads caused lasting harm, and the lawsuit continues.

Published:

Updated:

What happened

A US judge denied Novo Nordisk's bid to stop Eli Lilly's weight-loss drug advertisements. Novo Nordisk claimed the ads for Zepbound and Mounjaro were false and misleading. The judge said Novo Nordisk did not show the ads caused lasting harm, and the lawsuit continues.

Confirmed

Global impact / market context

The ruling lets Eli Lilly keep advertising its obesity and diabetes drugs against Novo Nordisk's Wegovy and Ozempic in a market worth tens of billions of dollars yearly. More ads can support prescriptions and revenue, while Novo Nordisk keeps spending on legal action without immediate relief.

Analyst inference

Both companies sell competing weight-loss and diabetes treatments, so advertising shapes which drug doctors and patients choose. The court found no proven sales threat yet, so investor attention stays on the ongoing lawsuit and whether ad spending shifts prescriptions and revenue between the two firms.

Analyst inference

What to watch

  1. Novo Nordisk said the ruling did not decide whether Lilly's advertising is false and misleading, and the litigation is still ongoing, so the legal case continues. Confirmed
  2. Watch whether Novo Nordisk seeks other court remedies or appeals, since the denied request was only for a preliminary injunction, which means a temporary order stopping the ads before a final ruling. Proposed
  3. Track Eli Lilly's advertising spending and prescription trends for Zepbound and Mounjaro, because continued ads could shift sales toward Lilly and raise costs for both companies. Analyst inference

Evidence